Follow along with the video below to see how to install our site as a web app on your home screen.
Note: This feature may not be available in some browsers.
Thanks ,I will ask people around see if someone knowsCan you ask if anyone figured out how to make NA-931 yet? The tradename is "Bioglutide".
Thanks for the pictures. Fascinating stuff!
Impossible, the molecular formula is not yet publicCan you ask if anyone figured out how to make NA-931 yet? The tradename is "Bioglutide".
Thanks for the pictures. Fascinating stuff!
Yeah good call. When do you think it will be public? I wonder if the UGL stuff will be injectable not oral because it seems like the drug delivery system would be quite complicated to mimick.Impossible, the molecular formula is not yet public
Tough to say for certain. If it's as exceptional as they advertise they will do anything and everything to prevent it from being public. It usually comes out in patent filings but companies use methods to delay it beyond that.Yeah good call. When do you think it will be public? I wonder if the UGL stuff will be injectable not oral because it seems like the drug delivery system would be quite complicated to mimick.
I don't know if this was a language model hallucination or something from the actual research but is the compound a metabolite of igf1 with cross receptor activation of GLP1?Tough to say for certain. If it's as exceptional as they advertise they will do anything and everything to prevent it from being public. It usually comes out in patent filings but companies use methods to delay it beyond that.
The IGF-1 receptor activation for a non-peptide small molecule is quite novel, and the moment it is public many companies will create structurally similar compounds to compete.
Depending on how Biomed proceeds, it could be public anytime from now until actual approval, likely in a few years at the latest.
Apparently so, you'd be right to be skeptical. Additionally, it's being combined with tirzepatide in trials which sounds quite redundant if it had relevant agonism to glp-1/gip.I don't know if this was a language model hallucination or something from the actual research but is the compound a metabolite of igf1 with cross receptor activation of GLP1?
If they figured out a way to avoid triggering hypertrophy in cardiomyocytes it would be a huge deal.
